Your browser doesn't support javascript.
loading
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
Briest, Franziska; Noerenberg, Daniel; Hennch, Cornelius; Yoshida, Kenichi; Hablesreiter, Raphael; Nimo, Jose; Sasca, Daniel; Kirchner, Marieluise; Mansouri, Larry; Inoue, Yoshikage; Wiegand, Laura; Staiger, Annette M; Casadei, Beatrice; Korkolopoulou, Penelope; Weiner, January; Lopez-Guillermo, Armando; Warth, Arne; Schneider, Tamás; Nagy, Ákos; Klapper, Wolfram; Hummel, Michael; Kanellis, George; Anagnostopoulos, Ioannis; Mertins, Philipp; Bullinger, Lars; Rosenquist, Richard; Vassilakopoulos, Theodoros P; Ott, German; Ogawa, Seishi; Damm, Frederik.
Afiliação
  • Briest F; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Noerenberg D; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Hennch C; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Yoshida K; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Hablesreiter R; Cancer Genome Project Wellcome Trust Sanger Institute, Hinxton, United Kingdom.
  • Nimo J; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Sasca D; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kirchner M; Department of Hematology, Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
  • Mansouri L; Core Unit Proteomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Inoue Y; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Wiegand L; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Staiger AM; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Casadei B; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
  • Korkolopoulou P; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart, and University of Tuebingen, Stuttgart, Germany.
  • Weiner J; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Lopez-Guillermo A; First Department of Pathology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • Warth A; Core Unit Bioinformatics Berlin, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schneider T; Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
  • Nagy Á; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Klapper W; National Institute of Oncology, Budapest, Hungary.
  • Hummel M; HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
  • Kanellis G; Department of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
  • Anagnostopoulos I; Department of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Mertins P; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bullinger L; Department of Hematopathology, Evangelismos General Hospital, Athens, Greece.
  • Rosenquist R; Department of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Vassilakopoulos TP; Institute of Pathology, University of Würzburg and Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany.
  • Ott G; Core Unit Proteomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Ogawa S; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Damm F; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Leukemia ; 37(11): 2237-2249, 2023 11.
Article em En | MEDLINE | ID: mdl-37648814
ABSTRACT
Recent exome-wide studies discovered frequent somatic mutations in the epigenetic modifier ZNF217 in primary mediastinal B cell lymphoma (PMBCL) and related disorders. As functional consequences of ZNF217 alterations remain unknown, we comprehensively evaluated their impact in PMBCL. Targeted sequencing identified genetic lesions affecting ZNF217 in 33% of 157 PMBCL patients. Subsequent gene expression profiling (n = 120) revealed changes in cytokine and interferon signal transduction in ZNF217-aberrant PMBCL cases. In vitro, knockout of ZNF217 led to changes in chromatin accessibility interfering with binding motifs for crucial lymphoma-associated transcription factors. This led to disturbed expression of interferon-responsive and inflammation-associated genes, altered cell behavior, and aberrant differentiation. Mass spectrometry demonstrates that ZNF217 acts within a histone modifier complex containing LSD1, CoREST and HDAC and interferes with H3K4 methylation and H3K27 acetylation. Concluding, our data suggest non-catalytic activity of ZNF217, which directs histone modifier complex function and controls B cell differentiation-associated patterns of chromatin structure.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histonas / Linfoma de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histonas / Linfoma de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha